Join the Truvada group to help and get support from people like you.
Truvada News
Long-Lasting HIV Prevention Shot Headed Toward Approval
FRIDAY, June 6, 2025 — A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month. If approved, the shot — lenacapavir — would be given t...
Initiation of HIV PrEP in Young Adults Rose in Recent Years
TUESDAY, June 3, 2025 – Dispensing and initiation of HIV preexposure prophylaxis (PrEP) among young adults increased from 2016 through 2023, according to a study published online May 9 in...
Eight Times More Young Adults Take Meds To Protect Against HIV Infection
FRIDAY, May 30, 2025 — Eight times more young Americans are taking antiretroviral meds to protect them from HIV infection than a decade ago, a new study says. About 208 of every 100,000 U.S. young a...
Half-Million Children Could Die If U.S. AIDS Relief Is Dropped
FRIDAY, April 11, 2025 — Nearly a half-million children could die from AIDS by 2030 if President Donald Trump follows through on plans to cut U.S. relief programs, a new study says. As many as 1 m...
U.S. Foreign Aid Cuts Could Devastate Global Progress Against HIV/AIDS
THURSDAY, March 27, 2025 – HIV could explode worldwide in the wake of U.S. cuts to foreign aid, resulting in millions of AIDS deaths and soaring rates of infection, a new analysis says. President...
Federal Judge Rules FDA, CDC Must Restore Health Websites Removed Under Trump Order
TUESDAY, Feb. 12, 2025 – A federal judge has ordered the U.S. Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) to restore access to public health websites that...
Trump Administration Waives Halt on Distribution of HIV Medications Via PEPFAR
WEDNESDAY, Jan. 29, 2025 – The Trump administration has made some concessions to the halt placed on distributions of global HIV treatments via the U.S. President's Emergency Plan for AIDS Relief...
Preexposure Prophylaxis Use for HIV Increased in Recent Years
MONDAY, Oct. 21, 2024 – Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 in the Journal of the American Medical ...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide) for HIV Pre-Exposure Prophylaxis (PrEP)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Oct. 3, 2019-- Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) approved a pre-exposure prophylaxis (PrEP) in...
FDA Approves Expanded Indication for Truvada (emtricitabine and tenofovir disoproxil fumarate) for Reducing the Risk of Acquiring HIV-1 in Adolescents
FOSTER CITY, Calif.--(BUSINESS WIRE)--May 15, 2018-- Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved once-daily oral Truvada...
FDA Approves Biktarvy (bictegravir, emtricitabine, tenofovir alafenamide) for Treatment of HIV-1 Infection
FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 7, 2018-- Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Biktarvy (bictegravir...
FDA Approves Descovy (emtricitabine and tenofovir alafenamide), Gilead’s Third TAF-Based HIV Therapy
FOSTER CITY, Calif., April 04, 2016 --(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Descovy® (emtricitabine 200 ...
FDA Approves Truvada for Reducing the Risk of Sexually Acquired HIV Infection
July 16, 2012 – Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected...
Further information
Related condition support groups
Pre-Exposure Prophylaxis, HIV Infection